Veradermics (MANE) Net Cash Flow (2025 - 2026)
Veradermics (MANE) posted Net Cash Flow of $146.6 million for Q1 2026, up 810.79% on a QoQ basis from -$20.6 million in Q1 2025, and up 810.79% year-over-year from $16.1 million in Q1 2025.
Veradermics (MANE) Net Cash Flow (2025 - 2026) Analysis & Trends
Veradermics' Net Cash Flow history runs 2 years deep, the most recent figure standing at $146.6 million for Q1 2026.
- Quarterly Net Cash Flow rose 810.79% year-over-year to $146.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.0 million (changed N/A YoY) and the FY2025 annual result came in at -$31.3 million, down 185.13% from the prior year.
- Net Cash Flow was $146.6 million for Q1 2026 at Veradermics, up from -$20.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $146.6 million in Q1 2026 and bottomed at -$20.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | 146.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.61 Mn |
| Mar 31, 2026 | 146.61 Mn |
| Mar 31, 2025 | -20.63 Mn |
| Mar 31, 2025 | -20.63 Mn |